Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 4:39 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 121 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Streptococcus Pneumoniae Infection Clear all

Conditions: Infection, Multiple Myeloma and Plasma Cell Neoplasm
Interventions: filgrastim, pneumococcal polyvalent vaccine, therapeutic autologous lymphocytes, therapeutic tumor infiltrating lymphocytes, carmustine, cyclophosphamide, melphalan, bone marrow ablation with stem cell support, peripheral blood stem cell transplantation; Biological · Drug · Procedure
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years to 80 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2008
U.S. locations: 2
States / cities: Baltimore, Maryland • Philadelphia, Pennsylvania

Conditions: PREVENTION OF INVASIVE PNEUMOCOCCAL DISEASE
Interventions: 13-valent pneumococcal conjugate vaccine, Seasonal Inactivated Influenza Vaccine, Placebo; Biological · Other
Lead sponsor: Pfizer; Industry
Eligibility: 50 Years and older
Enrollment: 882 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 44
States / cities: Birmingham, Alabama • Huntsville, Alabama • Scottsdale, Arizona + 37 more

Conditions: Pneumococcal Infections
Interventions: Multivalent, Tdap, polysaccharide; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 50 Years to 85 Years
Enrollment: 511 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 18
States / cities: Birmingham, Alabama • Cerritos, California • Savannah, Georgia + 12 more

Conditions: Pneumococcal Disease
Interventions: V116, PPSV23; Biological
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 2,162 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 30
States / cities: Mesa, Arizona • Tempe, Arizona • Little Rock, Arkansas + 27 more

Conditions: Pneumococcal Infections
Interventions: Multivalent, Prevnar 13; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 42 Days to 98 Days
Enrollment: 565 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 48
States / cities: Mobile, Alabama • Harrisburg, Arkansas • Anaheim, California + 34 more

Conditions: Healthy Volunteers, Pneumococcal Disease
Interventions: ASP3772, PCV13; Biological
Lead sponsor: Affinivax, Inc.; Industry
Eligibility: 12 Months to 15 Months
Enrollment: 75 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 17
States / cities: Bryant, Arkansas • Jonesboro, Arkansas • Anaheim, California + 14 more

Conditions: Pneumococcal Infections
Interventions: PCV21, 20vPCV; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 7 Months to 17 Years
Enrollment: 1,268 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 17
States / cities: Paramount, California • Doral, Florida • Hialeah, Florida + 13 more

Conditions: Chronic Bronchitis
Interventions: telithromycin; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 35 Years and older
Enrollment: 5,660 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Bacterial Pneumonia
Interventions: Ceftaroline fosamil for Injection, IV Ceftriaxone, Placebo, Clarithromycin; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 18 Years and older
Enrollment: 606 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 12
States / cities: Los Angeles, California • Pasadena, California • Sacramento, California + 9 more

Conditions: Infection in Solid Organ Transplant Recipients
Interventions: Pneumococcal Conjugate Vaccine 13 (PCV13); Biological
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 12 Months to 59 Months
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2025
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Pneumococcal Nasopharyngeal Colonization, Invasive Pneumococcal Disease
Interventions: Not listed
Lead sponsor: Johns Hopkins Bloomberg School of Public Health; Other
Eligibility: 7 Months and older
Enrollment: 6,628 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2012
U.S. locations: 2
States / cities: Whiteriver, Arizona • Gallup, New Mexico

Conditions: Pneumococcal Vaccines
Interventions: 0.5 ml dose of 1.1 mcg VAX-24, 0.5 ml dose of PCV20, 0.5 ml dose of 2.2 mcg VAX-24, 0.5 ml dose of 2.2/4.4 mcg VAX-24; Biological
Lead sponsor: Vaxcyte, Inc.; Industry
Eligibility: 42 Days to 89 Days
Enrollment: 802 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 32
States / cities: Jonesboro, Arkansas • Madera, California • Tampa, Florida + 22 more

Conditions: Herpes Zoster, Pneumococcal Infections
Interventions: Enhanced immunization delivery model, Immunization update; Behavioral · Other
Lead sponsor: Auburn University; Other
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 2
States / cities: Auburn, Alabama • Claremont, California

Conditions: Healthy Subjects, Pneumococcal Infections
Interventions: 13-Valent Pneumococcal Conjugate Vaccine (13vPnC), 7-Valent Pneumococcal Conjugate Vaccine (7vPnC); Biological
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 42 Days to 98 Days
Enrollment: 249 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2007
U.S. locations: 1
States / cities: New York, New York

Conditions: Pneumococcal Infections
Interventions: Prevnar 13™, V114, RotaTeq™, Pentacel™, RECOMBIVAX HB™, HIBERIX™, M-M-R™ II, VARIVAX™; Biological
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 42 Days to 90 Days
Enrollment: 900 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 22
States / cities: Birmingham, Alabama • Dothan, Alabama • Jonesboro, Arkansas + 16 more

Conditions: Cystic Fibrosis
Interventions: Throat Swab; Procedure
Lead sponsor: Tufts Medical Center; Other
Eligibility: 1 Day to 3 Months
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2011
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: HIV Infections
Interventions: Thalidomide; Drug
Lead sponsor: Rockefeller University; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: New York, New York

Conditions: Pneumococcal Disease
Interventions: 20vPnC; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 15 Months to 17 Years
Enrollment: 839 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 43
States / cities: Fayetteville, Arkansas • Jonesboro, Arkansas • San Diego, California + 30 more

Conditions: Pulmonary Disease, Chronic Obstructive, Pneumonia, Bacterial
Interventions: Bronchoscopy with bilateral bronchoalveolar lavages; Procedure
Lead sponsor: VA Ann Arbor Healthcare System; Federal
Eligibility: 18 Years to 80 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2021
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Meningococcal Meningitis, Measles, Mumps, Rubella, Varicella
Interventions: Menactra®: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate, Measles-mumps-rubella-varicella vaccine, Routine paediatric vaccine - Pneumococcal conjugate (PCV), Routine paediatric vaccine - Hepatitis A; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 9 Months to 12 Months
Enrollment: 1,378 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2009
U.S. locations: 78
States / cities: Birmingham, Alabama • Dothan, Alabama • Pinson, Alabama + 68 more

Conditions: HIV Infections, Pneumococcal Infections
Interventions: Pneumococcal Vaccine, Polyvalent (23-valent), Pneumococcal Conjugate Vaccine, Heptavalent, Placebo; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 2 Months to 6 Months
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1999
U.S. locations: 31
States / cities: Los Angeles, California • Oakland, California • San Diego, California + 21 more

Conditions: Vaccine, Pneumococcal Disease
Interventions: Pneumococcal Vaccine; Biological
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Pneumococcal Immunization, Healthy Volunteers
Interventions: PCV21 vaccine, 20vPCV licensed vaccine; Biological
Lead sponsor: Sanofi; Industry
Eligibility: 42 Days to 89 Days
Enrollment: 2,195 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 14
States / cities: Fayetteville, Arkansas • Huntington Park, California • Los Angeles, California + 10 more

Conditions: Pneumococcal Disease
Interventions: 31-valent pneumococcal conjugate vaccine, PCV20; Biological
Lead sponsor: Vaxcyte, Inc.; Industry
Eligibility: 50 Years and older
Enrollment: 752 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 30
States / cities: Chinle, Arizona • Phoenix, Arizona • Whiteriver, Arizona + 27 more

Search by objective public record fields.

Chemotherapy and Peripheral Stem Cell Transplantation Followed By Immunotherapy in Treating Patients With Multiple Myeloma

Concomitant Administration of 13-valent Pneumococcal Conjugate Vaccine (13vPnC) With Influenza Vaccine in 23-valent Pneumococcal Polysaccharide (23vPS) Pre-vaccinated Adults.

A Trial To Evaluate A Multivalent Pneumococcal Conjugate Vaccine In Healthy Adults 50-85 Years Of Age

A Study to Evaluate the Safety, Tolerability, Immunogenicity, and Lot Consistency of V116 in Adults 18 to 49 Years of Age (V116-004, STRIDE-4)

Study to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Vaccine Given With Prevnar 13 in Healthy Infants

A Study to Assess the Safety, Tolerability and Immunogenicity of ASP3772, a Pneumococcal Vaccine, in Toddlers 12 to 15 Months of Age in Comparison to an Active Comparator

Study of the Safety and Immunogenicity of Catch-up Vaccination With a 21-valent Pneumococcal Conjugate Vaccine (PCV21) in Healthy Infants, Toddlers, Children, and Adolescents

PERSPECTIVE: Telithromycin - Acute Exacerbation of Chronic Bronchitis

Comparative Study of Ceftaroline vs. Ceftriaxone in Adult Subjects With Community-Acquired Pneumonia

Pneumococcal Conjugate Vaccine 13 (Prevnar13®) in Children Who Are Solid Organ Transplant Recipients (SOT)

Impact of PCV on Disease and Colonization Among Native American Communities

Safety, Tolerability, and Immunogenicity of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Healthy Infants

Enhancing a Sustainable Pharmacy-based Immunization Program in Two States

Study Evaluating Pneumococcal Vaccine in Healthy Infants

A Study to Evaluate the Interchangeability of V114 and Prevnar 13™ in Healthy Infants (V114-027/PNEU-DIRECTION)

Microbiota of the Respiratory Flora in Children With Cystic Fibrosis During the First Year of Life

A Study of Thalidomide in HIV-Infected Patients Who Are Receiving HAART

Safety and Immunogenicity Study of 20vPnC in Healthy Children 15 Months Through 17 Years of Age

Modulation of Steroid Immunosuppression by Alveolar Efferocytosis

Study of the Safety of Menactra® Vaccine When Administered With Other Pediatric Vaccines to Healthy Toddlers

A Double-Blind Placebo-Controlled Trial of the Safety and Immunogenicity of a Seven Valent Pneumococcal Conjugate Vaccine in Presumed HIV-Infected Infants

Induction of Cross-protective Antibodies for Serogroup 33 by Pneumococcal Conjugate Vaccines

Lot-to-lot Consistency Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From 2 Months of Age

Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Prior Pneumococcal Vaccination